Mediacasts
- Uncharted Waters
- November 2008
Sandy Hillsberg, managing partner with Los Angeles-based law firm TroyGould, discusses how the global financial crisis is affecting emerging biotechnology companies.
- Harnessing Science
- September 2008
Dr. Louis Renzetti, vice president and global head of RNA therapeutics at Roche, explains the enormous potential of RNAi technology in the development of new medicines.
- A Common Path
- August 2008
Dr. Christian Weyer, vice president of clinical research at Amylin Pharmaceuticals, Inc. explains how the company’s current obesity therapy trials grew out of its diabetes program.
- Peaks and Valleys
- July 2008
Dr. Mario Raviglione, director of the Stop TB Department at the World Health Organization, outlines the successes and set backs in the global effort to end tuberculosis.
- BIOspeak
- June 2008
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), discusses the most pressing policy challenges facing the industry today.
- A New Gold Standard
- May 2008
John Doyle, DrPH, practice leader for market access at Quintiles Consulting, discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.
- A Shot in the Arm
- February 2008
Darrick Carter, Ph.D., director of formulations for the Infectious Disease Research Institute, discusses the numerous public/private partnerships involved in developing more effective vaccines for neglected diseases.
- Informed Choices
- January 2008
Dr. Scott Gottlieb, resident fellow at the American Enterprise Institute, explains how pharma’s future is dependent on sound public policy.
- Untapped Potential
- November 2007
Dr. Alessio Fasano of the University of Maryland School of Medicine talks about current research into the treatment and management of celiac disease.
- Innovation Through Collaboration
- October 2007
Joseph McCracken, vice president of business development at Genentech, discusses his company’s partnering philosophy.
- Legislating Drug Safety
- September 2007
Doug Peddicord, Ph.D., executive director of the Association of Clinical Research Organizations, explains the myriad drug safety initiatives being debated in the United States Congress this year.
- A Sense of Urgency
- August 2007
Stephen Lewis, former UN Special Envoy for HIV/AIDS in Africa and current co-director of AIDS-Free World, offers impassioned advice on HIV/AIDS in Africa.
- Progress for Parkinson’s
- July 2007
Dr. William Marks, associate professor of neurology at the University of California – San Francisco, and Dr. Melanie Brandabur clinic director at the Parkinson’s Institute, explain the concepts behind gene therapy for the treatment of Parkinson’s disease and discuss some of the challenges in researching neurodegenerative disorders.
- Planning Ahead
- June 2007
Dr. Klaus Kirchgässler, director of clinical affairs at Fournier (Solvay), gives advice for designing an optimal clinical development plan.
The views and opinions expressed in this podcast are strictly those of Dr. Kirchgässler and are not necessarily those of Solvay Pharmaceuticals.
- Blazing the Trail (part 2)
- May 2007
Dr. Janet Woodcock, chief medical officer at the U.S. Food and Drug Administration, explains the agency’s current thinking with regard to PDUFA renewal, post-marketing drug safety, pediatric studies and follow-on biologics.
- Blazing the Trail (part 1)
- April 2007
Dr. Janet Woodcock, chief medical officer at the U.S. Food and Drug Administration, discusses how some of the Critical Path Initiative’s key programs encourage innovation and optimize the drug development process.
- The Way Forward
- March 2007
Dr. Michael Krams, assistant vice president of adaptive clinical trials at Wyeth Research, discusses how innovative study design can lead to more efficient drug development and better patient care.
- A Culture of Drug Safety
- February 2007
Axel Olsen, Ph. D., president of the Pharmaceutical Safety Institute, discusses the need for system-wide reform of the drug safety paradigm.
